Related Experiment Video

Updated: Jun 4, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Targeting the FABP4-PPARγ axis with IPA improves obesity-related glomerulopathy

Sheng Li1, Yusheng Qin2, Jin Zou3

  • 1Affiliated Hengyang Hospital of Hunan Normal University & Hengyang Central Hospital, Hengyang City, China.

Biochimica Et Biophysica Acta. Molecular Basis of Disease
|June 2, 2026
PubMed

Insights

Indole-3-propionic acid (IPA) may treat obesity-related glomerulopathy (ORG) by stabilizing peroxisome proliferator-activated receptor γ (PPARγ). IPA disrupts the interaction between FABP4 and PPARγ, reducing renal fibrosis and lipid deposition.

Area of Science:

  • Nephrology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Obesity-related glomerulopathy (ORG) is a kidney disease linked to obesity, marked by fibrosis and lipid buildup.
  • The molecular drivers of ORG are not fully understood, requiring new therapeutic strategies.

Purpose of the Study:

  • To investigate the therapeutic potential of indole-3-propionic acid (IPA) in ORG.
  • To explore IPA's effects on key proteins, including fatty acid-binding protein 4 (FABP4) and peroxisome proliferator-activated receptor γ (PPARγ).

Main Methods:

  • Virtual screening identified FABP4 as a potential IPA target.
  • Protein expression and interaction studies were conducted.
  • IPA's impact on renal fibrosis and lipid deposition was assessed in a PPARγ-dependent manner.

Main Results:

  • IPA did not change FABP4 expression but increased PPARγ protein levels.
  • IPA competitively binds FABP4, disrupting the FABP4-PPARγ complex.
  • This interaction stabilizes PPARγ, reducing renal fibrosis and lipid accumulation.

Conclusions:

  • IPA modulates the FABP4-PPARγ axis, offering a potential therapeutic approach for ORG.
  • Targeting the FABP4-PPARγ interaction with IPA may mitigate obesity-induced kidney damage.
Keywords:
FABP4Indole-3-propionic acid (IPA)Obesity-related glomerulopathy (ORG)PPARγRenal fibrosis

More Related Videos

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...